Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer

doi:10.12998/wjcc.v8.i17.3718

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 17

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5786)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-6) series.

Item

Count

PDF

436

WORD

202

HTML

2378

Figures (1-4)

292

Tables (1-6)

211

Sum=3519

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

596

Download

1671

Sum=2267

Sep 6, 2020 (publication date) through Jul 24, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Cases. Sep 6, 2020; 8(17): 3718-3729
Published online Sep 6, 2020. doi: 10.12998/wjcc.v8.i17.3718

Open in New Tab Full Size Figure Download Figure

Figure 1 Progression-free survival (A) and overall survival (B) of each regimens.

Open in New Tab Full Size Figure Download Figure

Figure 2 Progression-free survival (A) and overall survival (B) of each regimens in below 3 of neutrophil/lymphocyte ratio.

Open in New Tab Full Size Figure Download Figure

Figure 3 Response of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio according to chemotherapy. NLR: Neutrophil/lymphocyte ratio; PLR: Platelet/lymphocyte ratio; GA: Gemcitabine plus nab-paclitaxel; FFX: FOLFIRINOX.

Open in New Tab Full Size Figure Download Figure

Figure 4 Progression-free survival (A) and overall survival (B) of each regimens in Eastern Cooperative Oncology Group 0 status.

Citation: Han SY, Kim DU, Seol YM, Kim S, Lee NK, Hong SB, Seo HI. Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer. World J Clin Cases 2020; 8(17): 3718-3729
URL: https://www.wjgnet.com/2307-8960/full/v8/i17/3718.htm
DOI: https://dx.doi.org/10.12998/wjcc.v8.i17.3718